HCPCS Q9956 is officially defined as "Injection, octafluoropropane microspheres, per ml." HCPCS Q9956 is referenced in 2 tracked payer policy changes from Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q9956 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
This is a reissue with no substantive changes to the contrast agents policy for echocardiography. The policy was reviewed and republished on 03/05/2025 as part of Independence Blue Cross's annual review process. Billing teams should verify their systems reflect the current coverage rules: contrast agents are separately reimbursable in office settings but included in facility procedure payments with no separate billing allowed.
Independence Blue Cross reissued Policy 09.00.11e with no substantive changes to contrast agent coverage for echocardiography. The policy confirms that contrast agents are covered in office settings with separate reimbursement eligibility, but are bundled into facility-setting procedure reimbursement with no separate billing allowed. This is a routine annual review reissue with the same coverage intent as the original 2021 policy.
Watch Q9956
Get one email when a payer policy names Q9956, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for Q9956
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for Q9956 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.